Institute Professor at the Koch Institute for Integrative Cancer Research at MIT, Philip Sharp says: “‘To personalize cancer care, we must interpret changes in cellular networks or mutations to predict the correct drug combination to use.’ In two studies focusing on a promising class of drugs for lung cancer called EGFR tyrosine kinase inhibitors, researchers have pinpointed new drug targets that could enhance the drugs’ activity. They hope the findings will enable a new approach to personalized cancer care, suggesting specific combinations of drugs that will be most effective for an individual’s cancer.”
Skilled hunters adapted to the changing landscape and left tantalizing clues to who they were.
Ways to move forward when you're wrong and I'm right.
Research suggests that to maintain a healthy brain, we should tend our gut microbiome.